ClinicalTrials.gov
ClinicalTrials.gov Menu

Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML (FLAGINEXOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03661515
Recruitment Status : Recruiting
First Posted : September 7, 2018
Last Update Posted : October 9, 2018
Sponsor:
Information provided by (Responsible Party):
PETHEMA Foundation

Brief Summary:

This protocol corresponds to a multicenter, open-label, non-randomized, phase I study designed to determine the safety of the combination of selinexor with chemotherapy in young patients with relapsed or refractory AML.

The clinical trial is divided into pre-treatment, treatment (induction and consolidation cycles) and follow-up periods and consists of a phase I design in which es-calating doses of selinexor will be given to 3 groups, each with 3-6 patients until achieving the maximum tolerated dose (MTD).


Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: Selinexor Drug: fludarabine Drug: idarubicin Drug: cytarabine Drug: G-CSF Phase 1

Detailed Description:

Study Design:

This protocol corresponds to a multicenter, open-label, non-randomized, phase I study designed to determine the safety of the combination of selinexor with chemotherapy in young patients with relapsed or refractory AML.

The clinical trial is divided into pre-treatment, treatment (induction and consolidation cycles) and follow-up periods and consists of a phase I design in which es-calating doses of selinexor will be given to 3 groups, each with 3-6 patients until achieving the maximum tolerated dose (MTD).

Each cycle (second induction, consolidation or maintenance) of treatment will compromise 3 weeks of selinexor treatment, and at least one week off treatment. The new cycle will not start if there is an ongoing grade 3 or higher non-hematologic toxicity or persistent grade 3 neutropenia in patients achieving CR.

Study design allows a maximum of 18 patients.

Induction cycle (up to 2 cycles):

Treatment will consist of fludarabine 30 mg/m2/day intravenously on days 1 to 4, idarubicin 10 mg/m2/day intravenously on days 1 to 3, cytarabine 2 g/m2/day intravenously on days 1 to 4, G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5. This schedule will be combined with oral selinexor (KPT-330) for three weeks at days and dose according to escalation level:

  • Level -1: Selinexor 40 mg/day, once weekly
  • Level 1: Selinexor 60 mg/day, once weekly
  • Level 2: Selinexor 80 mg/day, once weekly
  • Level 3: Selinexor 100 mg/day, once weekly If a partial response is obtained after the first cycle of treatment, an identical induction therapy will be administered.

If a patient achieves a complete remission after 1 or 2 cycles of FLAG-IDA plus selinexor, allogeneic stem cell transplantation (Allo-SCT) will be attempted. If Allo-SCT is not possible, this patient will receive consolidation treatment as described below.

Consolidation cycle (up to 2 cycles):

Treatment will consist of cytarabine 1 g/m2/day intravenously (3 hours) on days 1 to 6. This schedule will be combined with oral selinexor (the same dosage that was administered to the patient in the induction cycle).

At most, patients will receive up to 4 cycles of combined chemotherapy.

Maintenance cycle:

For patients in CR, and when an Allo-SCT is not feasible, a maintenance treatment with selinexor could be started for up to 6 cycles.

Selinexor will be given at the same level as during induction therapy in cycles of four weeks (3 weeks on selinexor and 1 week off).


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Investigator Sponsored Phase I Trial of Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML
Actual Study Start Date : July 17, 2018
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : December 2019


Arm Intervention/treatment
Experimental: Fludarabine-Idarubicine-Cytarabine- Selinexor

fludarabine 30 mg/m2/day intravenously on days 1 to 4, idarubicin 10 mg/m2/day intravenously on days 1 to 3, cytarabine 2 g/m2/day intravenously on days 1 to 4, G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5. This schedule will be combined with oral selinexor (KPT-330) for three weeks at days and dose according to escalation level:

  • Level -1: Selinexor 40 mg/day, once weekly
  • Level 1: Selinexor 60 mg/day, once weekly
  • Level 2: Selinexor 80 mg/day, once weekly
  • Level 3: Selinexor 100 mg/day, once weekly
Drug: Selinexor

According to escalation level:

  • Level -1: Selinexor 40 mg/day, once weekly
  • Level 1: Selinexor 60 mg/day, once weekly
  • Level 2: Selinexor 80 mg/day, once weekly
  • Level 3: Selinexor 100 mg/day, once weekly

Drug: fludarabine
fludarabine 30 mg/m2/day intravenously on days 1 to 4

Drug: idarubicin
idarubicin 10 mg/m2/day intravenously on days 1 to 3

Drug: cytarabine
cytarabine 2 g/m2/day intravenously on days 1 to 4

Drug: G-CSF
G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5




Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) of selinexor in combination with FLAG-Ida regimen [ Time Frame: At the end of Cycle 1 (each cycle is 56 days) ]

    A standard 3 + 3 dose escalation schedule will be used for all escalations. Initially, three patients will be entered in each cohort at the scheduled starting dose level for that cohort. If a drug-related DLT (see Section 5.1.5.3) is not seen at the scheduled dose, the dose will be escalated for the subsequent group of 3 patients.

    If 1 of 3 patients experiences a drug-related DLT, then 3 additional patients will receive that dose. If ≤ 2 of 6 patients experiences a drug-related DLT, the next scheduled dose level will be available. If, at a given dose level, > 2 patients experience a drug-related DLT, the MTD will have been exceeded, additional enrollment within that cohort will cease, and dose escalation will stop.

    If a dose level proves intolerable (≥ 3 patients experience a DLT), enrollment will proceed at one dose-level lower.


  2. Find recommended phase 2 dose [ Time Frame: 3 months ]

    A standard 3 + 3 dose escalation schedule will be used for all escalations. Initially, three patients will be entered in each cohort at the scheduled starting dose level for that cohort. If a drug-related DLT (see Section 5.1.5.3) is not seen at the scheduled dose, the dose will be escalated for the subsequent group of 3 patients.

    If 1 of 3 patients experiences a drug-related DLT, then 3 additional patients will receive that dose. If ≤ 2 of 6 patients experiences a drug-related DLT, the next scheduled dose level will be available. If, at a given dose level, > 2 patients experience a drug-related DLT, the MTD will have been exceeded, additional enrollment within that cohort will cease, and dose escalation will stop.

    If a dose level proves intolerable (≥ 3 patients experience a DLT), enrollment will proceed at one dose-level lower.



Secondary Outcome Measures :
  1. Assessment of toxicity: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 1 year ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.

  2. CR and CRi [ Time Frame: 3 months ]
    antileukemic effects, including its ability to produce complete remissions, of Selinexor in combination with chemotherapy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent in accordance with national, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure.
  • Age ≥ 18, and ≤ 65 years old.
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
  • Diagnosis of AML (defined using WHO criteria) of any type except for acute promyelocytic leukemia (APL; AML M3).
  • Relapsing or refractory AML, defined as either:

Recurrence of disease after first CR (duration of CR ≤ 24 months), or Failure to achieve CR or CRi after 1 or 2 identical induction cycles containing an anthracycline plus cytarabine based schedule.

  • No contraindications to receive intensive chemotherapy.
  • Female patients of child-bearing potential must have a negative serum pregnancy test at screening and agree to use two reliable methods of contraception for three months after their last dose of medication. Male patients must use a reliable method of contraception (if sexually active with a female of child-bearing potential).
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures.

Exclusion Criteria:

  • Patients with APL/AML M3.
  • Patients who are pregnant or lactating.
  • Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤ 2 weeks prior to Cycle 1 Day 1 or radio-immunotherapy 4 weeks prior to Cycle 1 Day 1. Hydroxyurea is permitted until 1 day prior to Cycle 1 Day 1.
  • Previous treatment with a SINE compound.
  • Major surgery within 2 weeks of first dose of study drug.
  • Any life-threatening illness, medical condition or organ system dysfunction which, in the Investigator's opinion, could compromise the patient's safety.
  • Unstable cardiovascular function:

    • Symptomatic ischemia, or uncontrolled clinically significant conduction abnormalities (i.e., ventricular tachycardia on anti-arrhythmia are excluded; 1st degree AV block or asymptomatic LAFB/RBBB will not be excluded), or congestive heart failure (CHF) of NYHA Class ≥ 3, or myocardial infarction (MI) within 3 months.
  • Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; however, prophylactic use of these agents is acceptable even if parenteral.
  • Active hepatitis B or hepatitis C infection.
  • Known human immunodeficiency virus (HIV) infection (HIV testing is not required as part of this study).
  • Patients unable to swallow tablets, patients with malabsorption syndrome, or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with absorption of study treatment.
  • Any of the following laboratory abnormalities unless due to leukemia:

    • Hepatic dysfunction: bilirubin > 2.0 times the upper limit of normal (ULN) (except patients with Gilbert's syndrome: total bilirubin of > 3 x ULN) and alanine aminotransferase (ALT) and aspartic aminotransferase (AST) > 2.5 times ULN or in case of liver metastases: In patients with known liver involvement of their cancer, AST and ALT > 5 x ULN.
    • Severe renal dysfunction: estimated creatinine clearance of < 30 mL/min, measured in 24 hour urine or calculated using the formula of Cockroft and Gault: (140-Age) x Mass (kg)/[72 x creatinine (mg/dL)]; multiply by 0.85 if female

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03661515


Contacts
Contact: Pau Montesinos, Dr +34 96 1245876 montesinos_pau@gva.es

Locations
Spain
Hospital Germans Tries i Pujol, Badalona Recruiting
Badalona, Spain
Contact: Susana Vives, Dr       svives@iconcologia.net   
Hospital San Pedro de Alcántara, Recruiting
Cáceres, Spain
Contact: Juan Bergua, Dr       jmbergua@icloud.com   
Hospital Universitario 12 de Octubre, Recruiting
Madrid, Spain
Contact: Pilar Martinez-Sanchez, Dr       mpmartinezsa@yahoo.es   
Hospital la Fe Recruiting
Valencia, Spain
Contact: Pau Montesinos, Dr       montesinos_pau@gva.es   
Sponsors and Collaborators
PETHEMA Foundation

Responsible Party: PETHEMA Foundation
ClinicalTrials.gov Identifier: NCT03661515     History of Changes
Other Study ID Numbers: FLAGINEXOR: IST-ESP-000155
First Posted: September 7, 2018    Key Record Dates
Last Update Posted: October 9, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by PETHEMA Foundation:
Acute Myeloid Leukemia
Relapsed
Refractory
Selinexor

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Leukemia
Neoplasms by Histologic Type
Neoplasms
Fludarabine
Fludarabine phosphate
Cytarabine
Idarubicin
Vidarabine
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antiviral Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors